Urotronic joins Laborie as part of its long-term expansion strategy, strengthening the Portsmouth-based medical device company.
Urotronic, Inc., a firm specializing in Optilume® drug-coated balloon technology for treating urethral strictures and BPH, has been acquired by Laborie Medical Technologies Corp.
As part of the transaction, Urotronic and its staff will be completely incorporated into the Laborie business. “We are delighted to welcome the Urotronic team to Laborie, and we look forward to working together in our mission to deliver innovative technologies in the Interventional Urology space that preserve and restore human dignity,” stated Michael Frazzette, President & CEO of Laborie Medical Technologies.
“Joining the Laborie team is an exciting new chapter for Urotronic,” adds David Perry, President & CEO of Urotronic. “Over the last several years, we have seen our partnership develop because we are united on a goal to improve the standard of care for patients and commercialize Optilume products on a global stage.”
“Patricia Industries is excited to continue supporting Laborie’s long-term growth with this acquisition, which aligns with our purpose of creating value for people and society by building strong and sustainable businesses,” added Yuriy Prilutskiy, Head of North America at Patricia Industries, a part of Investor AB and owner of Laborie Medical Technologies.
Optilume, a minimally invasive surgical procedure with FDA and CE mark approval, combines mechanical expansion with paclitaxel administration to treat LUTS caused by urological stricture or BPH.
